Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ocular Therapeutix (OCUL) Operating Expenses (2016 - 2025)

Ocular Therapeutix (OCUL) has 13 years of Operating Expenses data on record, last reported at $83.0 million in Q4 2025.

  • For Q4 2025, Operating Expenses rose 22.69% year-over-year to $83.0 million; the TTM value through Dec 2025 reached $322.0 million, up 36.72%, while the annual FY2025 figure was $322.0 million, 36.71% up from the prior year.
  • Operating Expenses reached $83.0 million in Q4 2025 per OCUL's latest filing, roughly flat from $83.2 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $83.2 million in Q3 2025 and bottomed at $27.6 million in Q1 2021.
  • Average Operating Expenses over 5 years is $47.5 million, with a median of $35.3 million recorded in 2023.
  • Peak YoY movement for Operating Expenses: rose 0.73% in 2022, then skyrocketed 94.14% in 2024.
  • A 5-year view of Operating Expenses shows it stood at $30.4 million in 2021, then grew by 10.14% to $33.4 million in 2022, then grew by 4.23% to $34.9 million in 2023, then soared by 94.14% to $67.7 million in 2024, then rose by 22.69% to $83.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Expenses were $83.0 million in Q4 2025, $83.2 million in Q3 2025, and $81.1 million in Q2 2025.